4/A: X4 Pharmaceuticals Executive Corrects Stock Appreciation Rights Award in Amended SEC Filing
SEC Filing
Christophe Arbet-Engels, Chief Medical Officer of X4 Pharmaceuticals, files an amendment to a Form 4 to correct the number of stock appreciation rights (SARs) awarded on February 13, 2024.
Summary
- Christophe Arbet-Engels, the Chief Medical Officer of X4 Pharmaceuticals, filed an amended Form 4 with the SEC on February 28, 2024.
- The amendment corrects an error in the original Form 4 filed on February 16, 2024, regarding the number of stock appreciation rights (SARs) awarded to him on February 13, 2024.
- The original filing incorrectly stated the number of SARs as 475,831, while the corrected number is 180,816.
- The SARs will vest in equal annual installments over three years, starting on February 13, 2025, contingent upon continued employment with X4 Pharmaceuticals.
Sentiment
Score: 7
Explanation: The document is a routine correction of an administrative error in an SEC filing. It doesn't indicate any fundamental change in the company's financial health or prospects.
Future Outlook
The stock appreciation rights will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.
Industry Context
This is a standard SEC filing related to executive compensation. It is common for companies to grant stock appreciation rights or other equity-based compensation to their executives.
Stakeholder Impact
- The correction of the stock appreciation rights award ensures accurate reporting to shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/13/2024 | Date of original transaction (award of stock appreciation rights) |
| 02/16/2024 | Date of original Form 4 filing (containing incorrect information) |
| 02/28/2024 | Date of amended Form 4 filing (correcting the information) |
| 02/13/2034 | Expiration date of the Stock Appreciation Right |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.